How Arrowhead and partners position Redemplo (plozasiran) on price and access after FDA approval for familial chylomicronemia syndrome (FCS), an ultra-rare but high-cost cardiometabolic niche.

Early hematology–oncology reaction to the FDA’s expanded approval of epcoritamab-bysp in follicular lymphoma, including community uptake and sequencing vs other CD20xCD3 bispecifics.

Whether device and biotech outperformance continues after Medtronic raised its growth outlook on strong heart device and pulsed field ablation (PFA) demand, while broader markets stay choppy.

FDA approves Redemplo (plozasiran) for ultra-rare FCS
The FDA cleared Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome, marking the 37th novel drug approval of 2025 and a high-profile win for RNA-interference in cardiometabolic disease. 👉 Read more

FDA expands epcoritamab-bysp to follicular lymphoma indications
The agency approved epcoritamab-bysp, a subcutaneous CD20xCD3 bispecific antibody, for additional follicular lymphoma settings, broadening its reach beyond diffuse large B-cell lymphoma and sharpening competition in B-cell malignancies. 👉 Read more

Medtronic raises full-year sales growth forecast on heart devices and PFA boom
Medtronic beat fiscal Q2 expectations and lifted its annual sales outlook, citing >300% pulsed field ablation growth and strong structural heart and cardiac rhythm performance, sending shares above $100 for the first time in years. 👉 Read more

Epcoritamab broadens its lymphoma footprint
The expanded epcoritamab-bysp label in follicular lymphoma strengthens bispecific antibodies as a core pillar in B-cell malignancies, with real-world safety and step-up dosing logistics remaining key watchpoints. 👉 Read more

IO Biotech updates phase 3 Cylembio data at Jefferies
IO Biotech presented updated phase 3 Cylembio results at the Jefferies Global Healthcare Conference, adding detail on survival and safety for its IO-based melanoma strategy as it courts partners and late-stage capital. 👉 Read more

Lifordi Immunotherapeutics lands strategic cash from Sanofi Ventures
Lifordi Immunotherapeutics announced a strategic investment from Sanofi Ventures plus follow-on capital from existing backers to advance its tumor microenvironment-focused immunotherapy pipeline, underscoring continued big-pharma interest in early oncology platforms. 👉 Read more

SC Launch backs Charleston cancer-immunotherapy startup
SC Launch, the South Carolina Research Authority’s investment arm, invested in a Charleston-based biotech developing novel cancer immunotherapies, adding regional capital to an already oncology-heavy funding day. 👉 Read more

Redemplo highlights maturing RNAi for cardiometabolic disease
With FDA’s approval in FCS, plozasiran adds to the growing list of RNA-targeting therapies moving beyond rare liver disorders into broader cardiometabolic territory, with triglyceride reduction and pancreatitis risk top of mind. 👉 Read more

Med-tech–academia alliance in Singapore to build next-gen device talent
BD Medical Products and Terumo Asia joined Duke-NUS Medical School’s innovation program to co-develop medtech curricula and translational projects, aiming to accelerate device innovation and commercialization in Asia. 👉 Read more

Wayne State highlights role in targeted AML inhibitor approval
Wayne State University profiled the physician-scientist who led pivotal studies supporting a recent FDA approval of a targeted inhibitor for NPM1-mutated AML, reflecting how academic centers continue to anchor precision oncology development. 👉 Read more

Medtronic leans into heart devices and PFA, stock breaks $100
Strong demand for pulsed field ablation and heart devices led Medtronic to raise its full-year sales growth forecast, highlighting PFA as one of medtech’s fastest-scaling franchises. 👉 Read more

Cornerstone’s $200M surgical-robotics raise continues to reverberate
Fresh analysis reiterated that Cornerstone Robotics’ ~$200M funding, disclosed in recent days, gives its Sentire endoscopic platform global expansion firepower and intensifies competition in soft-tissue robotics. 👉 Read more

Harrow closes acquisition of Melt Pharmaceuticals
Harrow completed its purchase of Melt Pharmaceuticals, adding sublingual and oral-dissolving sedation products (MELT-210/300/400) built on Zydis ODT technology to its ophthalmic-focused portfolio. 👉 Read more

Medicus Pharma provides Q3 update on microneedle and GnRH programs
Medicus Pharma updated investors on its doxorubicin microneedle array (D-MNA) and teverelix programs, flagging timelines for upcoming clinical milestones in oncology and men’s health. 👉 Read more

Lifordi Immunotherapeutics taps Sanofi Ventures
The strategic investment from Sanofi Ventures bolsters Lifordi’s balance sheet and signals continued big-pharma appetite for early oncology and immunology assets. 👉 Read more

New analysis exposes global gaps in access after FDA approvals
A study and ethics commentary in AJMC reported that lower-income countries often lack timely access to drugs tested in their populations and approved by the FDA, raising equity questions about trial participation and post-approval obligations. 👉 Read more

Investors press pharma to rethink growth in low- and middle-income markets
A new note urged pharma to revisit pricing and partnership models in LMICs, arguing that current strategies under-monetize long-term demand and invite political and reputational risk. 👉 Read more

Ultra-processed foods flagged as global public-health threat
Experts told Reuters that ultra-processed foods should be treated as a major health hazard akin to tobacco, increasing pressure on governments and industry to respond through regulation and product reformulation. 👉 Read more

Approvals are skewing toward targeted and rare
With Redemplo now the 37th novel drug of 2025 and focused on ultra-rare FCS, the approvals tape continues to tilt toward specialized, high-impact therapies rather than broad primary-care launches.

Hematology–oncology options keep expanding
The epcoritamab-bysp follicular lymphoma expansion and updated Cylembio data add competitive options in B-cell malignancies and melanoma, intensifying pressure on incumbents to differentiate on combinability, toxicity, and logistics.

Medtech is riding both PFA growth and outsourced manufacturing
Medtronic’s >300% PFA growth and a new market report projecting medical-device contract manufacturing to grow from $69.8B in 2023 to $191.4B by 2032 (11.9% CAGR) show the sector’s shift to specialized manufacturing partners and next-gen cardiac technologies.

Obesity market is being reshaped by pricing and side-effect strategies
Novo Nordisk is cutting cash-pay prices for Wegovy and Ozempic to about $349 via discount programs, while telehealth companies and platforms like GoodRx rapidly build GLP-1 subscription offerings, and Vanda is pushing an anti-emetic into phase 3 to manage Wegovy-related vomiting.

Biotech stocks are quietly recovering while the macro wobbles
Biotech and drug stocks outperformed broader indices today as investors sought defensiveness in healthcare, with sector commentary highlighting improving sentiment despite persistent macro volatility.

Novel drugs approved in 2025 so far: 37 (including Redemplo).

Device contract manufacturing market: projected from $69.75B (2023) to $191.4B (2032), 11.89% CAGR.

Medtronic PFA sales growth: >300% year-on-year in its fiscal Q2.

GLP-1 cash-pay anchor point: ~$349 per month for select Wegovy/Ozempic programs in U.S. discount offerings.

Street and payer commentary on Redemplo pricing and payer positioning in FCS and broader triglyceride management.

Deeper hematology–oncology analysis of epcoritamab’s expanded label and Cylembio’s updated phase 3 data.

Ongoing medtech coverage of Medtronic’s PFA trajectory, device contract manufacturing outlook, and follow-through on Cornerstone’s robotics expansion narrative.

XBI (SPDR S&P Biotech ETF): ~115.2, up about 0.3% on the day.

IBB (iShares Nasdaq Biotech ETF): ~166.5, up about 0.7%.

Sector tone: defensive but constructive, with healthcare outperforming a weaker broad market as investors lean into earnings visibility, M&A optionality, and obesity-driven growth.